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Abstract:

Background:
Microbiome feedbacks are proposed to influence Parkinson’s disease (PD) pathophysiology. A
number of studies have evaluated the impact of oral medication on the gut microbiome (GM) in PD.
However, the influence of PD device-assisted therapies (DATs) on the GM remains to be
investigated.

Objectives:
To profile acute gut microbial community alterations in response to PD DAT initiation.

Methods:
Clinical data and stool samples were collected from 21 PD patients initiating either Deep Brain
Stimulation (DBS) or levodopa-carbidopa intestinal gel (LCIG) and 10 spousal healthy control
(HC) subjects. 16S amplicon sequencing of stool DNA enabled comparison of temporal GM
stability between groups and with clinical measures, including disease alterations relative to therapy
initiation.

Results:
We assessed GM response to therapy in the PD group by comparing pre-therapy (-2 and 0 weeks)
with post-therapy initiation timepoints (+2 and +4 weeks) and HCs at baseline (0 weeks). Altered
GM compositions were noted between the PD and HC groups at various taxonomic levels,
including specific differences for DBS (overrepresentation of Clostridium_XlVa, Bilophila,
Parabacteroides, Pseudoflavonifractor and underrepresentation of Dorea) and LCIG therapy
(overrepresentation of Pseudoflavonifractor, Escherichia/Shigella, and underrepresentation of
Gemmiger). Beta diversity changes were also found over the 4 week post-treatment initiation
period.

Conclusions:
We report on initial short-term GM changes in response to the initiation of PD DATs. Prior to the
introduction of the DAT, a PD-associated GM was observed. Following initiation of DAT, several
DAT-specific changes in GM composition were identified, suggesting DATs can influence the GM
in PD.
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Introduction:
The progressive multisystem disorder Parkinson’s disease (PD) causes considerable morbidity, and
healthcare burden (1-4). It is generally accepted that PD pathology can originate outside of the
central nervous system (CNS) (5). This is hallmarked by Lewy body formation in the peripheral
nervous system and enteric nervous system (ENS), causing a progressive die-back of neurons into
the CNS that may lead to the development of clinical PD. Although gradual and irreversible
degeneration of neurons occurs throughout the brain, the loss of dopaminergic neurons in the
substantia nigra (6) is considered a defining feature of PD. Accordingly, the majority of available
PD treatments replace dopamine, although offer decreasing efficacy over time. In advanced PD,
when adjustments of conventional oral therapies fail to provide continued benefit (7, 8), the use of
device-assisted therapies (DATs), such as Deep Brain Stimulation (DBS) and levodopa-carbidopa
intestinal gel (LCIG), can substantially improve motor complications and health-related quality of
life (QoL) (9).

Recognition of an integrated bi-directional communication between the gut and brain via the ENS,
known as the gut-brain-axis, has led to increasing interest in the GM properties in PD as a
modulator of disease development and progression (10). Furthermore, some bacteria in the GM are
known to contribute to specific and host-independent metabolic processes that can impact on the
efficacy of PD medication, in particular the breakdown and/or modification of levodopa (11, 12).
Therefore, the community state (taxonomic bacterial composition and associated metabolic
functions) could influence PD treatment outcomes (13). Given the dynamic nature of gut
microbiomes in response to diet, environment and health status (14, 15), the GM may either be a
potential therapeutic target, or an adjunct tool for clinical management, informing relative health,
disease progression, long-term outcomes and response to therapy in PD (13, 16).

The influences of initiating DATs on the GM (e.g. brain to gut signalling influence from DBS and
direct gut influence of LCIG infusion) have not been systematically investigated, although recent
single study has observed several GM alterations from established LCIG therapy (17). Given the
potential reciprocal impacts of the GM on DAT, either may alter disease severity, progression or
therapeutic efficacy in an as yet unpredictable manner. The aims of this study were two-fold 1) to
characterise the GM composition differences between PD patients undergoing initiation of DATs
and healthy controls (HCs) and 2) to assess GM compositional changes over the short-term
introductory phase of DBS or LCIG in our PD cohort. This study highlights that there is a PD4

associated GM in patients awaiting DAT initiation and that introduction of a DAT can alter the GM
at least in the short-term.

Methods:

Study setting

Subjects attending clinics between June 2018–2019 were recruited from the movement disorder and
neurology clinics at Royal North Shore Hospital, Sydney, Australia. Ethical approval was granted
by the Northern Sydney Local Health District Human Research Ethics Committee
(HREC/18/HAWKE/109) and the North Shore Private Hospital ethics committee (NSPHEC 2018LNR-009) and all participants provided written informed consent.

Study subjects, device-assisted therapy initiation and sample collection

Participants were all >18 years of age, meeting specific criteria for recruitment to the PD and HC
groups and have been described previously (2). All participants were confirmed to have not had a
history of major GI disorder. PD patients provided fortnightly stool samples over a six-week period
around initiation of their DAT; t= -2, 0 (pre-therapy initiation), 2 and 4 weeks (post-therapy
initiation), as well as a blood sample at t=0. HCs provided one stool and blood sample at t=0
(Supplementary Figure 1). In total, 88 stool samples were collected, 78 from the PD and 10 from
the HC cohorts. Stool samples were assessed according to the Bristol Stool Scale (BSS) (18), whilst
non-fasting blood samples were commercially analysed by NSW Health Pathology, Royal North
Shore Hospital, Sydney, for liver function in addition to non-fasting lipid profiles, Erythrocyte
Sedimentation Rate and C-Reactive Protein.

For device initiation, LCIG patients had their tubes inserted by radiological guidance, with a staged
nasojejunal tube, followed by a gastrojejunostomy tube one week later. No antibiotics were
administered for either of those procedures. LCIG infusions were commenced at t=0, with a gradual
titration over the following 4 week interval. All DBS device introduction was performed by one
Neurosurgeon targeting the bilateral subthalamic nuclei. DBS patients required prophylactic
antibiotics at the time of surgery (t=0) to minimise risk of hardware infection; a standardised regime
of 1g intravenous Cephazolin given three-times daily for three consecutive days post operatively.
Apart from this, all participants did not take antibiotics or probiotic supplements for at least onemonth prior to each sample collection and did not receive any antibiotics throughout the entire
5

duration of the study. All PD patients were continued on their usual oral medications throughout the
follow-up period of the study, albeit with variable dosages determined by patient motor responses.
All LCIG patients had their oral levodopa substituted for the LCIG infusion, whilst most DBS
patients required oral levodopa reduction in response to initiating DBS.

Clinical data collection

All participants completed self-administered validated questionnaires at the t=0 interval that
collected socio-demographic factor, lifestyle, clinical management and comorbidity information. A
comprehensive Food Frequency Questionnaire (19, 20) was completed by all participants, allowing
for extrapolation of energy, protein, fat, carbohydrate, sugar and fibre intake. Upper gastrointestinal
symptoms were assessed by the Leeds Dyspepsia Questionnaire (LDQ) (21), constipation severity
by the Rome-IV criteria (22) and gut motility by the Cleveland Constipation Score (CCS) (23). QoL
was assessed by the PDQ-39 (24) and the Short Form Health Survey (SF-36) (25). Mood was
assessed by the Beck Depression Inventory (BDI) (26), cognitive function by the Montreal
Cognitive Assessment (MoCA) (27), whilst chronic pain severity was assessed by the Visual
Analogue Scale (28) and physical activity by the International Physical Activity Questionnaire
(IPAQ) (29).

For PD patients only, non-motor symptoms were evaluated by the Non-Motor Symptoms Scale
(NMSS) (30). Clinical motor assessments using the Movement Disorder Society – Unified
Parkinson’s Disease Rating Scale – Part III (MDS-UPDRS III) criteria (31) were performed by one
neurologist (ML) during a patient's ‘on’ state. PD medication use was calculated as daily levodopa
equivalent dose (LED) (32).

Faecal DNA extraction and 16S ribosomal RNA amplicon sequencing

Stool samples were collected into sterile pots, frozen and stored at -80ºC within 24 hours of
collection. Total faecal DNA isolation was carried out within 2 months of receiving stool samples
using an optimised protocol for the MP Biomedicals FastDNATM SPIN Kit for Faeces (MP
Biomedicals, Santa Ana, CA, USA). DNA integrity was confirmed by polymerase chain reaction
using universal primers to the V3–V4 regions (341f and 805r) and the whole rRNA gene (27f and
1492r) of bacterial 16S ribosomal DNA (33, 34).
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16S rRNA V3-V4 amplicon sequencing was performed by the Ramaciotti Centre for Genomics
(University of New South Wales, Sydney, Australia). Sequencing libraries were generated using
standard V3-V4 primers (341f and 805r (33)) and a two-stage amplicon and indexing PCR with
KAPA HiFi polymerase to generate 300bp paired-end reads. Libraries were purified after each PCR
using Ampure XP beads and normalised using the Applied Biosciences SequalPrep™ Plate
Normalization kit (Thermo Fisher). Sequencing was performed on an Illumina MiSeq platform
using MiSeq v3 chemistry with PhiX control v3. Additional internal sequencing controls included
replicate patient stool DNA samples and the ZymoBIOMICS Microbial Community DNA Standard
(Zymo Research, Irvine, CA, USA) for validation of sequencing.

Computational and statistical analyses
Clinical data comparisons between groups were performed by Student’s t-tests and χ2 tests for
quantitative and categorical variables, respectively, as well as Wilcoxon rank sum tests for nonnormally distributed data, using SPSS v.26 (SPSS Inc., Chicago, IL, USA). Variables were assessed
by Levene’s test to ensure homogeneity of variances. p<0.05 was considered statistically
significant. All statistical comparisons and data visualizations were performed with R (v.3.5.1) and
figures were generated with ggplot2 (v.3.1.0).

Pre-processing - The R-package dada2 (v.1.14.1) was used to process sequence data into amplicon
sequence variant (ASV) tables. The forward and reverse error profiles were trimmed to maintain
high quality (Supplementary Figure 2). A single LCIG t=2 sample was identified with low quality
reads and was excluded from analysis (Supplementary Figure 1). The sequences were trimmed from
37bp to 270bp and 10bp to 222bp in forward and reverse reads, respectively. Subsequently, the
sequence data was deduplicated to remove redundancy and combine all identical sequence reads
into an ‘unique sequence’. The dada2 method removed all substitution and indel errors. The
resulting sequence was further merged by removing paired sequences without perfect overlap.
Finally, the chimeras were removed by comparing the inferred sequence to others and removing
those that could be reproduced by stitching together two more abundant sequences. ASVs were
assigned to taxonomic groups according to Silva (v.138) reference database. The ASV tables were
further filtered with a prevalence of more than 10%, i.e. an ASV present in at least 10% of the total
sample or equivalently present in less than 9 subjects, to avoid noise or present rare taxa among the
samples.
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Microbiological community analysis - Alpha diversity metrics including the Shannon index and
taxon richness were calculated for each sample and a linear mixed effect (lme) model was used to
determine changes associated with time and PD treatment. Beta-diversity was analysed using the Rpackage vegan (v.2.5–3) to assess turnover between samples using a range of metrics, i.e. BrayCurtis (BC) dissimilarity, unweighted and weighted unifrac distance. A Principal Coordinate
Analysis (PCA) was used for both dimension reduction and visualizing the relationships among
samples. To assess the significance of beta diversity between treatments or time intervals, a
permutational multivariate analysis of variance (PERMANOVA) model was used. This model is
fitted via adnois2 function in vegan package with the argument “by” = “margins” and “perm”
=9999 for all comparisons. To compare the compositional difference across four time intervals, an
ANOVA-like differential expression (ALDE) model was used at four levels of taxonomic resolution
(phylum, order, family and genus). The data were compared for different sampling time intervals
(t=-2 vs t=0, t=0 vs t=2, t=2 vs t=4 and t=0 vs t=4) within the two DAT groups, with t=0 considered
baseline. The model was fitted using the R package ALDEx2 (v1.16). In the fitting of the ALDE
model, parameter mc.samples were set to 128 and denom=“All”. For the comparison of difference
between PD and HC groups, a similar ALDE model was fitted at t=0. In addition, a redundancy
analysis was used to examine clinical variable associations with the GM profile.

Results:

Cohort demographics and clinical characteristics
21 PD patients (10 initiating DBS and 11 LCIG) and 10 spousal matched HC’s were enrolled into
the study (Supplementary Figure 1). The HC’s were opportunistically chosen irrespective of the
type of therapy their spouse was initiating (2 DBS and 8 LCIG). 52% of the PD participants were
male with a mean age of 66.4 years, whilst 50% of the HC’s were male, with a mean age of 57.3
years (Table 1). Of the combined PD and HC cohort, over 80% of the participants were married and
identified as Caucasian. The mean last antibiotic use in the combined cohort was 18 months (range
1-72 months), with no difference between the groups (Table 1).
The mean age at diagnosis was 55.0 years and at sample recruitment was 66.4 for the PD cohort,
with a mean disease duration of 11.4 years (Table 2). All patients reported motor fluctuations and
medications ‘wearing off’ prior to their next dose, as well as dyskinesias in around 80% of patients.
Of the NMS, on average, 70% reported hyposmia and approximately half had Rapid Eye Movement
8

Sleep Behaviour Disorder. The mean daily LED was 1290mg and the mean ‘on’ MDS UPDRS-III
score was 43.4, with no apparent differences between the groups (Table 2).
The MDS–NMSS was different between DBS and LCIG patients, but did not reach statistical
significance for any of the domains. On the other hand, the QoL of LCIG patients was significantly
worse than DBS (p=0.019) (Table 2). DBS and LCIG patients received broadly similar oral PD
medication classes, with the only exceptions being anticholinergic use by one individual and
continuous apomorphine infusion in four individuals, from the LCIG group (Table 2).

Clinical characteristics
Of particular relevance to GM composition, PD patients experienced increased lower
gastrointestinal symptoms compared to HC’s, including increased constipation (Rome IV criteria),
more severe constipation (Rome IV and CCS) and harder stools (Bristol Stool Scale score),
indicative of slowed colonic transit times (Table 1). No differences in upper gastrointestinal
symptoms (LDQ) or physical activity (IPAQ) were noted between the groups. Chronic pain (Visual
Analogue Scale), depression (BDI) and mild cognitive impairment (MoCA) were more prevalent
for PD patients and QoL (SF-36) was reduced amongst PD patients from both a Physical and
Mental perspective (Table 1). Blood biochemistry results were largely unremarkable, aside from
lower mean albumin levels in the PD group, which may be indicative of mild malnutrition.
However, mean macronutrient intake did not differ between the groups, except for increased total
sugar intake in PD patients (Table 1).

Microbiome data for analysis
The total number of reads within the combined cohort was 5,898,893, with a mean depth of 64,823
reads per sample. These reads were assigned to 9084 ASVs. After filtering low abundance-ubiquity
(<10% of the sample or appeared in less than 9 samples), the final dataset had 625 ASVs. These
ASVs were further assigned to 14 phylum, 36 orders, 81 families and 219 genera.
Alterations in the gut microbiota between the Parkinson’s disease and healthy control cohorts
Comparison of the mean relative abundance at the family level for the 31 individual HC and PD
patients at baseline are presented in (Figure 1A). There was a statistically significant relative
abundance difference between the PD and HC groups (PERMANOVA; p=0.0033). Alpha diversity
(partitioning of biological space in each community), represented by Shannon (taxonomic richness)
9

and Simpson (taxon distribution) diversity, was not statistically different (ANOVA; p=0.72)
between HC and PD groups at baseline (t=0) (Figure 1B). Beta diversity (bacterial richness between
samples) was explored by PCoA with Bray-Curtis dissimilarity, unweighted unifrac and weighted
unifrac distance. Bray-Curtis ordination at the ASV level between the PD and HC groups (n=31) at
baseline (t=0), showed statistically significant differences in beta diversity (p=0.0042) between the
two groups (Supplementary Figure 3).

When matching available PD and HC cases at t=0 for potential confounding from geographic or
household factors (Figure 1C), variations in beta diversity between the two cohorts were identified
that were suggestive of a disease-related GM effect rather than a geographic or household effect
(PERMANOVA; p=0.0062).
Comparing PD with HC at t=0 showed statistically significant compositional differences at the
phylum, order, family and genus levels as illustrated in Figure 2, further indicative of PD-specific
GM profiles. The most differentially abundant taxa in PD patients were (1) overrepresentation of
Verrucomicrobia and underrepresentation of Firmicutes and Bacteroidetes at the phylum level, (2)
overrepresentation of Verrucomicrobiales and underrepresentation of Pasteurellales at the order
level, (3) overrepresentation of Verrucomicrobiaceae and underrepresentation of Pasteurellaceae
and Veillonellaceae at the family level, (4) overrepresentation of Akkermansia and
underrepresentation of Blautia, Faecalibacterium, Roseburia, Fusicatenibacter, Haemophilus,
Gemmiger, Butyricicoccus and Streptococcus at the genus level. The number of [ASVs] that were
assigned to each of these genera included, Akkermansia [3], Blautia [16], Faecalibacterium [9],
Roseburia [9], Fusicatenibacter [2], Haemophilus [1], Gemmiger [3], Butyricicoccus [7] and
Streptococcus [12].

Alterations in the gut microbiota in response to initiating DBS and LCIG therapies
Consistent with the combined PD cohort, mean relative abundance of bacterial taxa was similar
between DBS and LCIG groups across all sampling time points, with the phyla Bacteroidaceae
being the most abundant (Figure 3 and Supplementary Figure 4). Relative temporal stability of the
GM was identified during the two-week pre-treatment phase (t=-2 to t=0 interval) for the DBS and
LCIG cohorts.

For each DBS and LCIG patient as a fixed effect, lme modelling of alpha diversity (Figure 4A),
showed no statistically significant differences between the timepoints (pShannon=0.101,
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pSimpson=0.556), treatments (pShannon=0.527, pSimpson=0.612) and interactions (pShannon=0.776,
pSimpson=0.610). Thus, the alpha diversity of microbial communities from all 21 PD patients was
comparable across the sampling period and with HCs at baseline. Low alpha diversity outliers were
inconsistent over time (Figure 4A).

When considering pre and post-initiation time points, the beta diversity change between t=-2 to t=0
was much smaller than for post-treatment initiation time points, showing relative stability of pretreatment microbiome diversity (Figure 4B). The effects of DATs were considered at the ASV level
over the time course using Bray-Curtis ordination, showing statistically significant differences
(p=0.0102) between the DAT groups across the differing timepoints (Figure 4B).

To identify bacteria that may be impacted by the initiation of DBS or LCIG therapies, we used an
ALDE model to identify differentially represented taxa. The effect of treatment initiation was
compared between the intervals t=-2 vs t=0, t=0 vs t=2 and t=0 vs t=4 and hierarchically repeated
across four taxonomic levels (Figure 5). We identified significant changes in several taxa at order,
family and genus taxonomic levels for pre- vs post-treatment initiation sampling periods (Figure 5).
Each point in the plot represents a taxon, with the x-axis showing changes in t=-2 vs t=0 and the yaxis representing the changes from t=0 vs t=2 and t=0 vs t=4. The most differentially abundant taxa
after the initiation of DBS therapy (t=0 to t=2) included overrepresentation of ASVs assigned to
Clostridium_XlVa, Bilophila, Parabacteroides and Pseudoflavonifractor, and underrepresentation
of Dorea. Across the t=0 to t=4 interval only an overrepresentation of the genus Parabacteroides
persisted suggesting treatment effects were not sustained. Effects on the GM following initiation of
LCIG therapy identified differential abundance over the t=0 to t=2 interval for Enterobacteriaceae
(no genus within the family was significantly different). Across the t=0 to t=4 interval, a significant
difference in Escherichia/Shigella was observed and additionally Pseudoflavonifractor was also
overrepresented and Gemmiger underrepresented at the genus level.

When all PD patients undergoing DAT were considered (DBS and LCIG cohorts), the only
common GM difference was the overrepresentation of Pseudoflavonifractor between the t=0 to t=4
interval. This suggested GM responses to DAT initiation are both subtle and acute in nature (Figure
5).

Other factors influencing gut microbiota alterations
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Clinical and physiological functions that may mediate GM differences between PD patients and
HCs were also explored. A redundancy analysis with Bray-Curtis dissimilarity at a family
taxonomic level identified statistically significant associations of clinical and biochemical variables
with GM profiles (Supplementary Figure 5). For instance, Verrucomicrobiaceae abundance was
associated with increased constipation severity, as defined by the Rome-IV criteria. Whereas BSS
and HbA1c associated with the abundance of Lachnospiraceae, particularly within the HC cohort.
Additionally, age, male gender, BMI, CRP and total cholesterol levels associated with broader GM
profiles, particularly those observed in the PD cohort.

Notable changes in stool consistency on the BSS were apparent for many patients initiating DBS
and LCIG over the sampling period (Supplementary Figure 6). As such, the relationship between
the BSS and the GM was examined by evaluating beta diversity changes using PCoA with BrayCurtis dissimilarity at a family taxonomic level for DBS and LCIG patients (Supplementary Figure
7). This showed a statistically significant variation to GM composition as a result of longitudinal
BSS fluctuations (p=0.009).

Discussion:

This is the first acute longitudinal study of the PD GM to evaluate the impact of initiating peripheral
and direct GM interacting DATs (DBS and LCIG). We identified temporal stability in the GM of
PD patients over a two-week pre-DAT initiation interval and also showed PD-specific microbiota
differences when compared to HCs. Following initiation of DATs, further variation in GM
composition was apparent in PD patients over a 4 week post-initiation sampling period.

Comparison of GM differences between the PD and HC cohorts at t=0 in this study showed
consistency with earlier PD GM studies (35-41). The common overrepresentation of
Verrucomicrobia (due to Akkermansia) in PD cohorts, including the cohort studied here, is
suggestive of a higher proportion of mucolytic communities (42). These organisms occupy a
common region of the gut at the mucosal lining but have disparate nutritional and stress-response
strategies and are typically seen to increase in relative abundance during periods of fasting or
reduced gut motility (43). This may be indicative of alterations to the gut environment, driven by
changes in production and turnover of mucin, that may alter gut motility and could in part drive PD
pathology (43). Consistently, increased upper GI dysfunction and increased constipation severity
was identified in the PD cohort studied here (2), in conjunction with overrepresentation of
Akkermansia, which has been associated with increased constipation severity (44). Furthermore, we
12

identified an underrepresentation of Gemmiger, which has not previously been reported in other PD
GM studies, supporting a PD-specific GM existed in this study. Consistently, altered microbiota
abundances have been reported in treatment naïve PD patients compared to HCs (36, 38, 45).

To date, two long-term longitudinal studies evaluating disease progression and temporal stability of
the PD GM have been conducted (46, 47), without consideration for PD therapy. Other studies have
attempted to unravel the effects of standard medications on the GM, namely catechol-Omethyltransferase inhibitors and levodopa, although most participants were taking multiple oral PD
medications simultaneously and only a single timepoint was analysed (35-37, 39-41, 48). In
addition, one published longitudinal study has directly investigated GM alterations in response to
initiating oral levodopa, with selective GM compositional changes noted over a 2 week period (49).
However, preliminary findings from another study suggested that oral levodopa-carbidopa did not
impact the GM over a 90-day follow-up period (50).

Potential causes or consequences of the observed PD GM composition differences may include
disrupted intestinal motility, as well as fasting and nutritional changes peri-procedurally. This raises
an important point as to whether gut dysmotility is a driver of GM changes, changes in the GM
composition cause gut dysmotility, or if there is reciprocal feedback that progressively impacts both
composition and gut dysmotility. Previous PD GM studies have shown a reduction in short-chain
fatty acid–producing bacteria (eg. Blautia, Roseburia, Faecalibacterium, Butyricicoccus) (51),
which may result in detrimental effects that include increased colonic inflammation, gut leakiness,
increased risk of α-syn deposition in the GI tract, and microglial activation in the brain (16, 52).
Furthermore, short-chain fatty acids are the major energy substrate of mitochondria in colonocytes
of the proximal colon, which may contribute to mechanical insufficiency, impaired active transport
of metabolites and other energy dependent functions in this important region of the large intestine
(53). The observed GM imbalances may also reflect environmental factors that trigger pathological
processes in already susceptible PD patients, as microbiota are known to be exquisitely susceptible
to environmental changes. Therefore, compositional changes in PD may represent noxious
environmental factors that trigger and promote disease progression, a theory compatible with the
recent rise of PD incidence in developed nations (52).
It is estimated that ~150,000 PD patients have already received DBS worldwide (8), with 5−10% of
patients attending movement disorder clinics in high-income countries projected to undergo DBS
during the course of their disease (54). Interestingly, in earlier cross-sectional PD GM studies, DAT
patients, namely DBS, were either excluded from enrolment or analysed as part of a combined PD
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cohort (35, 37, 46, 55, 56), aside from a recent study evaluating established LCIG influences on the
GM (17). Here, we aimed to evaluate the potential GM modulatory effects due to initiation of DBS
and LCIG therapies within a cohort of advanced PD patients. To assess the treatment effects on the
GM, potential clinical and medication confounders were considered and minimised across the 6
week sampling period. All existing patient medications, including the four patients receiving
apomorphine infusions in the LCIG group, were continued during their respective DAT initiation,
although dosages of certain medications did vary in accordance with required therapeutic efficacy.
All participants were asked to continue on their regular diets during the study, although both the
DBS and LCIG cohorts required fasting periods of <12 hours pre-device implantation procedure. In
addition, the DBS cohort required a standard three-day course of intravenous Cephazolin postoperatively to minimise the risk of hardware infection. This first-generation beta-lactam antibiotic is
not expected to cause substantial GM alterations compared to other antimicrobial classes, due to its
clinical preference for treating skin and soft tissue infection (57, 58). Its use however, may reflect
why a greater number of taxa differences were observed in this group, between t=0 and t=2;
overrepresentation of Desulfovibrionales, Clostridium_XlVa, Bilophila, Parabacteroides and
Pseudoflavonifractor and underrepresentation of Dorea. Whilst, over the t=0 to t=4 interval only an
increased abundance of the genus Parabacteroides persisted, which when coupled with the
observed overrepresentation of Clostridium, could be considered an expression of antiinflammatory symbionts (59).

When considering the LCIG group, an overrepresentation of Enterobacteriales and
Enterobacteriaceae was seen from the t=0 to t=2 interval, whilst across the t=0 to t=4 interval an
overrepresentation of Pseudoflavonifractor and Escherichia/Shigella were accompanied by an
underrepresentation of Gemmiger. This is of particular relevance given the potential GM
modulatory effects that continuous levodopa-carbidopa gel infusion into the small bowel may have
downstream. The mildly acidic (~pH 6.0) properties of LCIG may potentially explain an
overrepresentation of Escherichia/Shigella observed in LCIG patients in the cohort studied here,
given these bacteria can cause invasive stomach disease, implying they are more tolerant of acidic
conditions (60). It has also been suggested that LCIG may affect the GM metabolism, acting as a
stressor in precipitating an inflammatory intestinal microenvironment, although these effects are
still poorly characterised (17). The observed GM differences between the groups may be resultant
of the direct (LCIG) versus indirect (DBS) nature of the two therapies on the GM or the specific
phenotypic variability that makes certain PD patients suitable for the different DATs.
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Another potential confounding factor to the observed GM alterations in the DAT cohorts was the
potential effect of constipation severity and gut transit times (2, 61), indicated by variable BSS
before and after the initiation of DAT. BSS is known to correlate with GI dysfunction and likely
influences taxa abundances. It was previously shown that stool consistency negatively correlated
with species richness, which was positively associated to the Bacteroidetes:Firmicutes ratio, and
linked to Akkermansia and Methanobrevibacter abundance (61). Similarly, PD patients with a lower
mean Rome-IV score in this study showed overrepresentation of Verrucomicrobiaceae.
Furthermore, a previous study found that the initiation of DBS improved gastrointestinal symptoms,
namely dysphagia, constipation, feeling of fullness and gastric emptying, when assessed at three
months post-surgery (62).

Whilst our data does not address certain potential confounding factors, including other
comorbidities and non-PD medication effects, medication for GI dysfunction (e.g., laxatives, antidiarrhoea medication and reflux medication), several important GM related DAT differences were
identified in the longitudinal PD cohort. The relatively short 4 week follow-up period after DAT
initiation did not allow for the evaluation of potential delayed GM compositional changes to each
therapy. Large cohorts of DAT patients can be challenging to recruit, meaning small sample sizes
may not provide optimal statistical power to resolve all GM differences of relevance. In addition,
non-optimally matched PD and HC groups for age and sex, due to spousal recruitment, may have
resulted in potential confounding in the comparative GM analysis. The use of antibiotics in the DBS
cohort was described earlier as a significant limitation, however it was considered unethical not to
provide antibiotics to this cohort of subjects, due to an inherent risk of hardware infection. The
findings of this study should therefore be interpreted in light of their limitations, notably the
fluctuations in patient gastrointestinal function due to periprocedural fasting, bowel motion
changes, evident by constipation / BSS fluctuation and medication alterations in the short follow-up
period. Future larger and longer studies evaluating the influences of DAT on the GM should also
examine participants initiating subcutaneous apomorphine infusions, as the third commonly utilised
DAT in PD, data which was not available in our cohort. In addition, examination of potential
clinical and GM associations resulting from DAT initiation by the use of shotgun metagenomic
sequencing, which offers a finer degree of taxonomic resolution and insight to bacterial metabolic
function, would also be insightful.

Conclusion:
15

In our cohort of PD patients initiating DAT, we showed that the initiation of both DBS and LCIG
therapies reflected notable GM compositional changes. GM temporal stability was identified over a
2-week pre-initiation period in our PD cohort, allowing comparison of GM compositional
differences between the PD and HC groups, as well as for DAT groups across the acute posttherapy initiation sampling period. The identified variations in GM composition were in many
regards comparable to other studies. The compositional changes across studies appear to signify an
emerging trend supporting the presence of proinflammatory and mucus degrading microbiota
communities that may increase intestinal barrier permeability and cause gut leakiness. Future longterm longitudinal analysis of the effects of these GM changes in both the DBS and LCIG cohorts
will be of interest to evaluate sustained GM compositional differences, as well as to analyse
whether there are favourable clinical motor and non-motor outcomes, frequently observed with the
introduction of DATs.
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Figure Legends:
Figure 1: Measures of microbiota abundance and diversity between healthy control (HC) and
Parkinson’s disease (PD) groups. A. The relative abundance of phylogenetic gut microbiome taxa
composition at the family level for individual participants, (n=10 HCs, n=10 DBS and n=11 LCIG),
at baseline (t=0) showed compositional differences between PD and HC groups (PERMANOVA;
p=0.0033). B. Box plots representing alpha diversity showed no significant differences in Shannon
(species abundance and evenness within a community) or Simpson (species richness and evenness
within a community) diversity between the HC and PD (subdivided into the advanced therapies
groups; Deep Brain Stimulation (DBS) and Levodopa-Carbidopa Intestinal Gel (LCIG)) cohorts at
t=0. C. Geographic / household matched HCs (n=10) and PD (n=10) patients were compared by
Principal Coordinate Analysis with weighted unifrac at the Amplicon Specific Variant level for t=0.
Comparison of the first three principal components revealed varied beta diversity (extent of species
diversity difference between two environments) between the groups, suggestive of a disease-related
effect on GM composition (PERMANOVA; p=0.0062) that defines a PD-related GM composition.
Coloured ellipses represent 90% confidence region and the proportion of total variance represented
by a given principal component is labelled on the respective axis.
Figure 2: Comparison of taxa abundance between healthy controls (HC) and Parkinson’s
disease (PD) patients at different phylogenetic levels reveals specific differences. Volcano plots
representing abundance differences (fold change) of different taxa between HC and PD patients at
baseline (t=0) showed statistically significant (-log(p) >3; fold change >±2) compositional
differences at the genus, family, order and phylum levels (represented by red dots), indicative of a
PD-related GM composition. With regard to PD patients, there was statistically significant A.
overrepresentation of Akkermansia and underrepresentation of Blautia, Faecalibacterium,
Roseburia, Fusicatenibacter, Haemophilus, Gemmiger, Butyricicoccus and Streptococcus at the
genus level, B. overrepresentation of Verrucomicrobiaceae and Pasteurellaceae and
underrepresentation of Veillonellaceae at the family level, C. overrepresentation of
Verrucomicrobiales and of Pasteurellales at the order level, D. overrepresentation of
Verrucomicrobia and underrepresentation of Firmicutes and Bacteroidetes at the phylum level.
Figure 3: Taxa abundances in individual Parkinson’s disease patients before initiating Deep
Brain Stimulation (DBS) or Levodopa-Carbidopa Intestinal Gel (LCIG) Device-Assisted
Therapy (DAT). The relative abundance of phylogenetic gut microbiome taxa composition, at the
family level for individual patients from the A. DBS (n=10) and B. LCIG (n=11) groups at all four
28

timepoints (pre-initiation, t= -2 and t=0 weeks; post-initiation t=2 and t=4 weeks) revealed greater
changes in abundances post-DAT initiation (e.g. t=2 and t=4, compared to t= -2 and t=0),
implicating a direct impact of DATs on GM composition.

Figure 4: Longitudinal gut microbiota diversity of device assisted therapy (DAT) patients
initiating deep brain stimulation (DBS) or levodopa-carbidopa intestinal gel (LCIG). A. Alpha
diversity indices Shannon (species abundance and evenness within a community) and Simpson
(species richness and evenness within a community) diversity, were considered across the
longitudinal sampling period (t= -2, 0, 2, 4 weeks post-DAT initiation) for DBS and LCIG patients,
with comparison to healthy controls (HC) at baseline (t=0) only. Overall, no statistically significant
diversity differences were noted between the DAT groups or with HCs across all four-time
intervals. However, a smaller degree of alpha diversity variation was noted pre-DAT initiation (t= 2 to t=0), compared to post-DAT initiation (t=0 to t=4). B. Beta diversity (extent of difference in
species diversity difference between two environments) for the DBS and LCIG groups was
determined across the different periods (t=-2 to t=0, t=0 to t=2, t=2 to t=4 and t=0 to t=4) using
Principal Coordinate Analysis with Bray-Curtis (BC) dissimilarity at the Amplicon Specific Variant
level. Overall, a statistically significant beta diversity difference was noted between the two DAT
cohorts (p=0.0102). Post-DAT initiation (t=0 vs t=2, t=0 vs t=4 and t=2 vs t=4) showed increasing
differences between timepoints for the same individuals (indicated by the longer intervals on the
PCoA plot). This is most evident when comparing to pre-DAT initiation (t= -2 vs t=0).
Figure 5: Comparative analysis of gut microbiota abundance changes in Parkinson’s disease
patients between pre and post-device assisted therapy (DAT) initiation. An ALDE model was
used to test for changes in gut microbiome taxa abundance across post-DAT initiation periods (t=0
vs t=2 weeks and t=0 vs t=4 weeks) against changes in abundance across the pre-DAT initiation
(t=0 vs t= -2) period. This is performed separately for the deep brain stimulation and levodopacarbidopa intestinal gel groups at the phylogenetic levels phylum, order, family and genera,
resulting in a total of 8 analyses. The results for each analysis is presented as a scatter plot, where
each point represents a taxon, with the x-axis representing the -log(p) of pre-DAT initiation change
from t= -2 to t=0 and the y-axis representing the -log(p) of the post-DAT initiation changes between
t=0 to t=2 (green) and t=0 to t=4 (orange). Overall, certain taxa were differentially represented with
statistical significance (indicated by taxon names).
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Tables
Table 1: Cohort Demographic and Clinical Characteristics

Number of Subjects (n=)
Age (years) [SD, Range]

Parkinson’s
Disease
21
66.4 [9.9,
41-81]

Healthy
Control
10
57.3 [12.7,
40-73]

Gender (%)
Male
Female
Marital Status (%)

52.4
47.6

Married / de facto
Single
Widowed
Ethnicity (%)

85.7
9.5
4.8

Caucasian
Asian
Middle Eastern
Other
Body Mass Index [SD]
Last Antibiotic Use (months) [SD,
Range (months)]
Smoking History (%)
Current Smoker
Prior Smoker

Test Statistic
(df)

p value

t=2.2 (29)^

0.037

χ2=0.2 (1)∞

0.901

χ2=1.6 (2)∞

0.453

χ2=2.3 (3)∞

0.509

W=106.5#
t=-0.3 (29)^

0.772
0.839

50.0
50.0
100.0
0
0

81.0
4.8
9.5
4.8
24.6 [5.9]
18.7 [18.8,
1-72]

60.0
10.0
10.0
20.0
25.1 [3.6]
17.4 [10.6,
1-36]

0
23.8

0
20.0

χ2=0.1(1)∞

0.813

50.0

90.0

χ2=4.6 (1)∞

0.032

< Weekly

19.0

10.0

χ2=0.4 (1)∞

0.522

Several Times Weekly

28.6

50.0

χ2=1.4 (1)∞

0.244

Daily

4.8

30.0

χ2=3.8 (1)∞

0.050

80.9

90.0

χ2=0.4 (1)∞

0.522

1.8 [1.7]

2.5 [1.1]

t=-1.2 (29)^

0.242

9.5

10

0.967

9559 [2181]
101.4 [23.8]
94.0 [34.6]
234.0 [60.1]
135.0 [40.8]
34.3 [11.1]
9.5

8784 [2597]
93.3 [34.2]
85.1 [35.5]
195 [58.3]
93.9 [35.4]
29.4 [15.9]
0

χ2=0.1 (1)∞
t=1.1 (27.5)^
t=1.1 (27.3)^
t=0.9 (22.2)^
t=0.8 (28)^
t=2.5 (27.9)^
t=1.1 (27.1)^

Alcohol Consumption (%)

Caffeine Consumption (Coffee/Tea)
(%)
Number of Daily Cups [SD]
Dietary Intake
Vegetarian Diet (No Meat) (%)
Energy (kcal/day) [SD]
Protein (g/day) [SD]
Fat (g/day) [SD]
Carbohydrate (g/day) [SD]
Total Sugars (g/day) [SD]
Fibre (g/day) [SD]
History of Diabetes (%)

χ2=1.0 (1)∞

0.285
0.301
0.381
0.101
0.018
0.271
0.313

Gastrointestinal Symptoms
30

Cleveland Constipation Score
[SD]
Constipation Score as per ROME
IV Criteria [SD]
Functional Constipation as per
ROME IV Criteria (%)
Bristol Stool Score [SD]
Leeds Dyspepsia Questionnaire
(LDQ) Score [SD]
Chronic Pain Over Last 3 Months
(%)
Pain Score (Visual Analogue
Scale) [SD]
International Physical Activity
Questionnaire (IPAQ) Score (METminutes/week) [SD]
Sitting Hours/Day [SD]
Depression Characteristics
Beck’s Depression Inventory
Total Score [SD]
Beck’s Depression Inventory
Categories (%)
Minimal Depression (0-13)
Mild Depression (14-19)
Moderate Depression (20-28)
Severe Depression (39-63)
Clinically Depressed (>13 for
Parkinson’s Disease and >9 for
Control groups), (%)
Montreal Cognitive Assessment
(MoCA) [SD]
MoCA Total Score ( /30)
Mild Cognitive Impairment
(<26/30) (%)
Parkinson’s Disease Dementia
(<21/30) (%)
36 Item Short Form Health Survey
(Quality of Life Assessment) [SD]
Health Change Over Last Year
Physical Component Summary
Mental Component Summary
Biochemical Characteristics [SD]
Erythrocyte Sedimentation Rate
C-Reactive Protein
Total Cholesterol
Low Density Lipoprotein
High Density Lipoprotein
Triglycerides
Random Glucose
HbA1c%
Albumin

8.1 [5.1]

2.2 [1.8]

t=4.8 (27.1)^

<0.001

5.1 [3.5]

0.9 [1.1]

t=4.9 (26.9)^

<0.001

90.5

30.0

χ2=12.0 (1)∞

0.001

2.1 [1.1]
8.4 [8.7]

4.0 [1.2]
3.6 [4.5]

t=-4.3 (29)^
W=69#

<0.001
0.240

85.7

40.0

χ2=6.9 (1)∞

0.009

4.8 [2.5]

4.0 [2.2]

t=0.6 (20)^

0.552

863.8
[805.4]

1610.1
[1987.8]

t=-1.5 (29)^

0.144

7.4 [3.1]

6.3 [2.2]

t=4.7 (29)^

0.333

15.4 [11.3]

3.5 [4.0]

W=14#

<0.001

χ2=8.1 (3)∞

0.044

χ2=5.1 (1)∞

0.024

W=140#
χ =4.8 (1)∞

0.040
0.029

47.6%
28.6%
9.5%
14.3%
52.4%

100.0%
0%
0%
0%
10.0%

23.1 [5.8]
61.9

27.2 [2.2]
20.0

23.8

-

25.0 [15.8]
42.1 [18.9]
50.7 [25.1]

50.0 [0]
81.0 [15.5]
87.3 [8.2]

t=-4.9 (29)^
t=-5.7 (29)^
t=-4.6 (29)^

<0.001
<0.001
<0.001

7.7 [5.1]
5.2 [10.6]
4.6 [0.7]
2.7 [0.6]
1.3 [0.4]
1.3 [0.6]
5.8 [0.7]
5.3 [0.4]
35.5 [4.2]

7.8 [4.9]
2.1 [1.6]
5.1 [1.1]
2.8 [0.9]
1.5 [0.4]
1.8 [1.1]
5.8 [0.3]
5.2 [0.2]
39.9 [2.1]

W=100.5#
W=93.5#
t=-1.4 (29)^
t=-0.3 (29)^
W=116#
W=136#
t=0.7 (29)^
t=0.4 (29)^
W=150#

0.900
0.220
0.164
0.768
0.335
0.062
0.952
0.752
0.011

2
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^(Two sample t-test); ∞(Pearson’s chi-squared test); #(Wilcoxon rank sum test); [SD] (Standard deviation); df
(degrees of freedom)

Table 2: Parkinson’s Disease Patient Clinical Characteristics

Number of Patients (n=)
Age (years) [SD]
Age at Diagnosis (years) [SD]
Parkinson’s Disease Duration (years)
[SD]
Parkinson’s Disease Phenotype (%)
Tremor Dominant
Postural Instability and Gait
Impairment
Akinetic Rigid
Young Onset (<40 years)
Late Onset (>60 years)
Disease Complications (%)
Motor Fluctuations
Dyskinesia
Wearing off
Impulse Control Disorder
Non-motor Symptoms (%)
Hyposmia
REM Sleep Behaviour Disorder
Levodopa Equivalent Daily Dose
(mg) [SD]
MDS Unified Parkinson’s Disease
Rating Scale (‘on’ state) [SD]
Parkinson’s Disease Therapy (%)
Oral Levodopa
Dopamine Agonist
Monoamine Oxidase B Inhibitor
Anticholinergic
Catechol-O-methyltransferase
Inhibitor
Amantadine

DBS
Cohort
10
65.8 [9.2]
53.6 [7.2]
12.2 [4.2]

LCIG
Cohort
11
67.0 [11.0]
56.3 [9.1]
10.6 [4.9]

Test Statistic
(df)

p
value

t=0.8 (19)^
t=0.7 (19)^
t=-0.8 (19)^

0.790
0.466
0.423

χ2=2.9 (3)∞

0.400

50.0
20.0

18.2
27.3

30.0
0
30.0

45.5
9.1
36.4

χ2=0.1 (3)∞

0.757

100.0
70.0

100.0
90.9

χ2=1.5 (1)∞

0.223

100.0
20.0

100.0
27.3

χ2=1.5 (1)∞

0.696

70.0

72.7

χ2=0.1 (1)∞

0.890

40.0

63.6

0.279

1175.7
[213.9]
35.5 [13.6]

1404.4
[372.0]
51.2 [22.2]

χ2=1.2 (1)∞
t=1.7 (19)^
t=1.9 (19)^

0.069

100.0
60.0

100.0
63.6

χ2=0.3 (1)∞

0.864

20.0

18.2

χ2=0.1 (1)∞

0.916

0

9.9

χ2=0.9 (1)∞

0.329

40.0

45.5

χ2=0.1 (1)∞

0.801

10.0

18.2

χ2=0.3 (1)∞

0.593

0.105
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Apomorphine (Subcutaneous
Infusion)
Quality of Life
PDQ-39 Summary Index [SD]
MDS Non-Motor Symptoms Score
(NMSS) – Total Score [SD]
Cardiovascular [SD]
Sleep / Fatigue [SD]
Mood and Cognition [SD]
Perceptual Problems [SD]
Attention and Memory [SD]
Gastrointestinal [SD]
Urinary [SD]
Sexual [SD]
Miscellaneous [SD]

0

36.4

χ2=4.5 (1)∞

0.034

29.6 [11.9]
69.4 [61.7]

46.1 [17.0]
106.4 [50.2]

t=2.6 (19)^
W=28#

0.019
0.062

2.5 [2.1]
13.8 [10.4]
10.2 [11.6]
1.5 [1.6]
8.2 [10.3]
6.0 [5.7]
10.4 [11.7]
7.0 [11.6]
9.8 [8.2]

4.9 [3.7]
22.6 [9.9]
20.7 [22.2]
6.3 [7.4]
6.5 [5.8]
10.9 [ 7.6]
12.6 [ 9.7]
8.5 [5.2]
13.5 [8.9]

t=1.8 (19)^
t=1.9 (19)^
W=31.5#
W=26.5#
W=52#
W=31#
W=42#
W=34#
t=1.0 (19)^

0.087
0.063
0.188
0.061
0.633
0.110
0.376
0.721
0.340

^(Two sample t-test); ∞(Pearson’s chi-squared test); #(Wilcoxon rank sum test); [SD] (Standard deviation); df
(degrees of freedom)
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The impact of device-assisted therapies on the gut microbiome in
Parkinson’s disease.
Supplementary Figures

Supplementary Figure 1:
Recruitment of Parkinson’s disease and healthy control participants. Participants
provided biospecimens at various time intervals for 16S amplicon sequencing analysis of the
gut microbiome or routine biochemical blood tests. (*) A t=+2 sample from a LevodopaCarbidopa Intestinal Gel (LCIG) participant had to be removed from analysis due to low
quality reads. Two Deep Brain Stimulation (DBS) and four LCIG participants were unable to
provide a t= -2 stool specimen. Following 16S sequencing, taxonomic profiling was used to
assess differences between groups and therapies, temporal stability and clinical associations
with the gut microbiome.

Supplementary Figure 2:
A representative selection of three participant samples showing raw-paired sequencing read
quality (R1 in the left column, R2 in the right column). Reads were trimmed somewhere
between 200 and 300 bases to give read quality scores >30. The total number of reads per
sample is shown in red in the bottom left of each plot.

Supplementary Figure 3:
Beta diversity differences between the studied cohorts. Principal coordinate component
analysis with Bray-Curtis dissimilarity of beta diversity at the amplicon sequencing variant
level for the first three principal components between the healthy control and Deep Brain
Stimulation (DBS) and Levodopa-Carbidopa Intestinal gel (LCIG) cohorts at baseline (t=0,
indicated by triangle symbol) showed a statistically significant difference in beta diversity
(p=0.0042). Subsequent evaluation of the effects of DBS and LCIG to the gut microbiome at
the amplicon sequencing variant level, after therapy initiation (t=0 vs t=2, t=2 vs t=4 and t=0
vs t=4), indicated a statistically significant trend toward increasing beta diversity for both the
DBS and LCIG groups in response to treatment initiation (p=0.0102).

Supplementary Figure 4:
Mean relative abundance of microbiota around initiation of Parkinson’s disease device
assisted therapy. Relative abundance differences across the sampling period (t= -2 to t=4
weeks) for the device-assisted therapies, Deep Brain Stimulation (DBS) and LevodopaCarbidopa Intestinal gel (LCIG) cohorts, across A. phylum, B. family and C. genera
taxonomic levels showed comparable mean relative abundances between the two deviceassisted therapy groups over the four time intervals. However, a statistically different mean
relative abundance between the DBS and LCIG groups was noted compared to the healthy
control participants at baseline (t=0; p=0.0033).

Supplementary Figure 5:
Associations between microbiota and clinical measures. Redundancy analysis with BrayCurtis dissimilarity was used at the family taxonomic level to identify clinical / and
biochemical variables that associated with microbiota abundances. Verrucomicrobiaceae
abundance was associated with increased constipation severity as defined by the Rome-IV
criteria. Whereas Bristol Stool Scale score and Hemoglobin A1c associated with the
abundance of Lachnospiraceae, particularly within the healthy control cohort. Additionally,
age, male gender, Body Mass Index, C-reactive protein and total cholesterol levels associated
with broader microbiota profiles, particularly those observed in the Parkinson’s disease
cohort.
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Supplementary Figure 6:
Variability of Bristol Stool Scale score around initiation of Parkinson’s disease deviceassisted therapy. Bristol Stool Scale scores across sampling intervals (t= -2, 0, 2, 4 weeks)
for individuals within the Deep Brain Stimulation (DBS) and Levodopa-Carbidopa Intestinal
gel (LCIG) cohorts were similarly variable when compared to healthy control scores at
baseline (t=0). This indicated that the initiation of Parkinson’s disease device-assisted
therapies did not have an immediate impact on Bristol Stool Scale score post-initiation. Mean
Bristol Stool Scale scores at the t=0 interval for the DBS 1.9 (SD 1.0), LCIG 2.3 (SD 1.1)
and health control 4.0 (SD 1.2) participants.

Supplementary Figure 7:
Beta diversity influences from the effects of changing Bristol Stool Scale scores over
time. Principal coordinate component analysis with Bray-Curtis dissimilarity of beta
diversity at the family taxonomic level for the first three principal components between the
healthy control, Deep Brain Stimulation (DBS) and Levodopa-Carbidopa Intestinal gel
(LCIG) cohorts showed a statistically significant difference in beta diversity in response to
longitudinally changing Bristol Stool Scale scores (p=0.009).

